A Phase I-II Study of the Efficacy and Safety of Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes.

Trial Profile

A Phase I-II Study of the Efficacy and Safety of Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Azacitidine (Primary) ; Idarubicin (Primary)
  • Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Dec 2016 This trial has been completed in France (end date: 9 May 2016).
    • 28 Oct 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017 as per ClinicalTrials.gov record.
    • 28 Oct 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top